SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND) today announced that it expects fiscal 2008 revenues to be between $65 million and $75 million. Previously the Company expected fiscal 2008 revenues to be between $80 million and $85 million, and is revising guidance based primarily on expectations of product approval delays in China, as well as uncertainty regarding possible approval delays in Japan. The revised guidance also reflects slower-than-anticipated sales in North America.
